Assessment of cannabis use disorders: A systematic review of screening and diagnostic instruments

Psychological Medicine

Volumn 45, Issue 6, 2015, Pages 1121-1133

  Lopez Pelayo H ^a   Batalla, A ^b,c   Balcells, M M ^a   Colom, J ^d   Gual, A ^a  

^a Institute of Neurosciences   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

Author keywords

Assessment; cannabis; instruments; screening; THC

Indexed keywords

DEVICES; HUMAN; MARIJUANA ABUSE; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; QUESTIONNAIRE; STANDARDS;

HUMANS; MARIJUANA ABUSE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; SURVEYS AND QUESTIONNAIRES;

EID: 84925237188     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714002463     Document Type: Review

References (61)

1. Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, Sellman JD (2010). An improved brief measure of cannabis misuse: The Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug and Alcohol Dependence 110, 137-143.
2. Alexander D, Leung P (2006). The Marijuana Screening Inventory (MSI-X): concurrent, convergent and discriminant validity with multiple measures. American Journal of Drug and Alcohol Abuse 32, 351-378.
3. Anderson P, Gual A, Colom J (2005). Alcohol and Primary Health Care: Clinical Guidelines on Identification and Brief Interventions. Department of Health of the Government of Catalonia: Barcelona.
4. Angold A, Costello EJ (1995). A test-retest reliability study of child-reported psychiatric symptoms and diagnoses using the Child and Adolescent Psychiatric Assessment (CAPA-C). Psychological Medicine 25, 755-762.
5. Annaheim B, Rehm J, Gmel G (2008). How to screen for problematic cannabis use in population surveys: an evaluation of the Cannabis Use Disorders Identification Test (CUDIT) in a Swiss sample of adolescents and young adults. European Addiction Research 14, 190-197.
6. Barry KL, Fleming MF, Greenley J, Widlak P, Kropp S, McKee D (1995). Assessment of alcohol and other drug disorders in the seriously mentally-ill. Schizophrenia Bulletin 21, 313-321.
7. Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, Nogue S, Torrens M, Pujol J, Farre M, Martin-Santos R (2013). Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLOS ONE 8, e55821.
8. Berman AH, Bergman H, Palmstierna T, Schlyter F (2005). Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. European Addiction Research 11, 22-31.
9. Burns RM, Caulkins JP, Everingham SS, Kilmer B (2013). Statistics on cannabis users skew perceptions of cannabis use. Frontiers in Psychiatry 4, 138.
10. Butcher JN, Williams CL, Graham JR, Archer RP, Tellegen A, Ben-Porath YS, Kaemmer B (1992). MMPI-A Minnesota Multiphasic Personality Inventory-A: Manual for Administration, Scoring and Interpretation. University of Minnesota Press: Minneapolis.
11. Cascini F, Aiello C, Di Tanna G (2012). Increasing delta-9-tetrahydrocannabinol (delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Current Drug Abuse Reviews 5, 32-40.
12. Colón HM, Pérez CM, Meléndez M, Marrero E, Ortiz AP, Suárez E (2010). The validity of drug use responses in a household survey in Puerto Rico: comparison of survey responses with urinalysis. Addictive Behaviors 35, 667-672.
13. Conway KP, Levy J, Vanyukoy M, Chandler R, Rutter J, Swan GE, NealeM (2010). Measuring addiction propensity and severity: the need for a new instrument. Drug and Alcohol Dependence 111, 4-12.
14. Copeland J, Gilmour S, Gates P, Swift W (2005). The Cannabis Problems Questionnaire: factor structure, reliability, and validity. Drug and Alcohol Dependence 80, 313-319.
15. Cuenca-Royo AM, Sanchez-Niubo A, Forero CG, Torrens M, Suelves JM, Domingo-Salvany A (2012). Psychometric properties of the CAST and SDS scales in young adult cannabis users. Addictive Behaviors 37, 709-715.
16. Denis C, Lavie E, Fatseas M, Auriacombe M (2006). Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database of Systematic Reviews Issue 3. Art. No.: CD005336. doi:10.1002/14651858.CD005336.pub2
17. European Monitoring Centre for Drugs and Drug Addiction (2012). 2012 Annual report: the state of the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction. Luxembourg: Publications Office of the European Union (emcdda.europa.eu). Accessed September 2014.
18. Fagerstrom KO, Schneider NG (1989). Measuring nicotine dependence - a review of the Fagerstrom tolerance questionnaire. Journal of Behavioral Medicine 12, 159-182.
19. Fernandez-Artamendi S, Fernández-Hermida JR, García-Cueto E, Secades-Villa R, García-Fernández G, Barrial-Barbén S (2012a). Adaptación y validación española del Adolescent-Cannabis Problems Questionnaire (CPQ-A). Adicciones 24, 41-49.
20. Fernandez-Artamendi S, Fernández-Hermida JR, Muñiz-Fernández J, Secades-Villa R, García-Fernández G (2012b). Screening of cannabis-related problems among youth: the CPQ-A-S and CAST questionnaires. Substance Abuse Treatment Prevention and Policy 7, 13.
21. Gheorghiev C, Arvers P, de Montleau F, Fidelle G, Queyriaux B, Verret C (2009). Cannabis in the army: between past and topicality. Annales Medico-Psychologiques 167, 429-436.
22. Grant BF, Harford TC, Dawson DA, Chou PS, Pickering RP (1995). The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Drug and Alcohol Dependence 39, 37-44.
23. Gual A, Martos AR, Lligona A, Llopis JJ (1999). Does the concept of a standard drink apply to viticultural societies? Alcohol and Alcoholism 34, 153-160.
24. Hall W (2009). The adverse health effects of cannabis use: what are they, and what are their implications for policy? International Journal of Drug Policy 20, 458-466.
25. Hall W, Degenhardt L (2009). Adverse health effects of non-medical cannabis use. Lancet 374, 1383-1391.
26. Hurd YL, Michaelides M, Miller ML, Jutras-Aswad D (2014). Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology 76, 416-424.
27. Johns A (2001). Psychiatric effects of cannabis. British Journal of Psychiatry 178, 116-122.
28. Johnson BD, Golub A (2007). The potential for accurately measuring behavioral and economic dimensions of consumption, prices, and markets for illegal drugs. Drug and Alcohol Dependence 90, S16-S26.
29. Jungerman FS, Laranjeira R (2008). Characteristics of cannabis users seeking treatment in Sao Paulo, Brazil. Revista Panamericana De Salud Publica - Pan American Journal of Public Health 23, 384-393.
30. Kader R, Seedat S, Koch JR, Parry CD (2012). A preliminary investigation of the AUDIT and DUDIT in comparison to biomarkers for alcohol and drug use among HIV-infected clinic attendees in Cape Town, South Africa. African Journal of Psychiatry 15, 346-351.
31. Kaner EFS, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N (2009). The effectiveness of brief alcohol interventions in primary care settings: a systematic review. Drug and Alcohol Review 28, 301-323.
32. Karila L, Legleye S, Beck F, Corruble E, Falissard B, Reynaud M (2007). Validation of a questionnaire to screen for harmful use of alcohol and cannabis in the general population: CRAFFT-ADOSPA. Presse Medicale 36, 582-590.
33. Kerr WC, Stockwell T (2012). Understanding standard drinks and drinking guidelines. Drug and Alcohol Review 31, 200-205.
34. Lavender JM, Looby A, Earleywine M (2008). A brief cannabis-associated problems questionnaire with less potential for bias. Human Psychopharmacology - Clinical and Experimental 23, 487-493.
35. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar GC (1997). The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. European Psychiatry 12, 224-231.
36. Lennox R, Dennis ML, Scott CK, Funk R (2006). Combining psychometric and biometric measures of substance use. Drug and Alcohol Dependence 83, 95-103.
37. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 62, e1-e34.
38. López-Pelayo H, Balcells-Oliveró MM, Gual-Solé A (2013). Lack of cannabis consumption registry. Actas Espanolas De Psiquiatria 41, 208.
39. Mariani JJ, Brooks D, Haney M, Levin FR (2011). Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes. Drug and Alcohol Dependence 113, 249-251.
40. Marimoutou C, Queyriaux B, Michel R, Verret C, Haus-Cheymol R, Mayet A, Deparis X, Boutin J-P (2010). Survey of alcohol, tobacco, and cannabis use in the French Army. Journal of Addictive Diseases 29, 98-106.
41. Martin G, Copeland J, Gilmour S, Gates P, Swift W (2006). The Adolescent Cannabis Problems Questionnaire (CPQ-A): psychometric properties. Addictive Behaviors 31, 2238-2248.
42. Martin GW, Pearlman S, Li S (1998). The test-retest reliability of the frequency of multiple drug use in young drug users entering treatment. Journal of Substance Abuse 10, 275-290.
43. McClure EA, Stitzer ML, Vandrey R (2012). Characterizing smoking topography of cannabis in heavy users. Psychopharmacology 220, 309-318.
44. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA (2010). Potency trends of delta 9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. Journal of Forensic Sciences 55, 1209-1217.
45. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 6, e1000097.
46. Norberg MM, Mackenzie J, Copeland J (2012). Quantifying cannabis use with the Timeline Followback approach: a psychometric evaluation. Drug and Alcohol Dependence 121, 247-252.
47. Pedersen ER, Grow J, Duncan S, Neighbors C, Larimer ME (2012). Concurrent validity of an online version of the Timeline Followback assessment. Psychology of Addictive Behaviors 26, 672-677.
48. Piontek D, Kraus L, Klempova D (2008). Short scales to assess cannabis-related problems: a review of psychometric properties. Substance Abuse Treatment Prevention and Policy 3, 25.
49. Proudfoot H, Vogl L, Swift W, Martin G, Copeland J (2010). Development of a short cannabis problems questionnaire for adolescents in the community. Addictive Behaviors 35, 734-737.
50. Reinert DF, Allen JP (2007). The alcohol use disorders identification test: an update of research findings. Alcoholism, Clinical and Experimental Research 31, 185-199.
51. Rodríguez TJ, Valdés CM, Fernández AM, Dalbosco D, Hoffman SM, Fernanda Flores OM, Javiera Lee AM, Ramírez RF, Ramírez PE, Pruzzo GM (2011). Drug consumption in the masculine school population using the peer methodology and The Standard Self Assessment Questionnaire. Terapia Psicologica 29, 159-165.
52. Serre F, Fatseas M, Debrabant R, Alexandre J-M, Auriacombe M, Swendsen J (2012). Ecological momentary assessment in alcohol, tobacco, cannabis and opiate dependence: a comparison of feasibility and validity. Drug and Alcohol Dependence 126, 118-123.
53. Stein LAR, Graham JR (2001). Use of the MMPI-A to detect substance abuse in a juvenile correctional setting. Journal of Personality Assessment 77, 508-523.
54. Stein LAR, Lebeau R, Clair M, Rossi JS, Martin RM, Golembeske C (2010). Validation of a measure to assess alcohol- and marijuana-related risks and consequences among incarcerated adolescents. Drug and Alcohol Dependence 109, 104-113.
55. Thake J, Davis CG (2011). Assessing problematic cannabis use. Addiction Research and Theory 19, 448-458.
56. Tiet QQ, Finney JW, Moos RH (2008). Screening psychiatric patients for illicit drug use disorders and problems. Clinical Psychology Review 28, 578-591.
57. Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R (2004). Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. American Journal of Psychiatry 161, 1231-1237.
58. Urrutia G, Bonfill X (2010). PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses. Medicina Clinica 135, 507-511.
59. Voluse AC, Gioia CJ, Sobell LC, Dum M, Sobell MB, Simco ER (2012). Psychometric properties of the Drug Use Disorders Identification Test (DUDIT) with substance abusers in outpatient and residential treatment. Addictive Behaviors 37, 36-41.
60. Weintraub WS, Klein LW, Seelaus PA, Agarwal JB, Helfant RH (1985). Importance of total life consumption of cigarettes as a risk factor for coronary-artery disease. American Journal of Cardiology 55, 669-672.
61. WHO ASSIST Working Group (2002). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction (Abingdon, England) 97, 1183-1194.